Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study
Polycystic Ovary Syndrome · Insulin Resistance Syndrome
Enrolment: 128 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Polycystic Ovary Syndrome · Insulin Resistance Syndrome
Enrolment: 128 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Transient middle cerebral artery occlusion, 60 min occlusion followed by reperfusion for 24 h
A single intravenous dose of rhMG53 at 3 mg/kg given 30 min before ischaemia or up to 4 h after reperfusion reduced infarct area, improved Zea-Longa scores at 24 h, reduced TUNEL positivity and caspase-3 activation, and restored Akt and GSK3-beta phosphorylation. Benefit was lost when dosing was de…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
Model: Ischaemia-reperfusion and overventilation-induced acute lung injury, emphysema and chronic lung injury models, with anoxia and reoxygenation in cultured lung epithelial cells
MG53-deficient mice were more susceptible to ischaemia-reperfusion and overventilation lung injury. Extracellular recombinant human MG53 protected cultured lung epithelial cells and, given intravenously or by inhalation, reduced injury in rodent models of acute lung injury and emphysema, with repea…
Extraction: extract · Supplied extraction confidence: 0.62. Machine-extracted fields require source verification.